Cytek Biosciences, Inc. (CTKB) stock
CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/306% below fair value
$5.92+0.22 (+3.86%)
Close on Nov 18, 2026Market cap $769.50MP/E –Yield –
Cytek Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Cytek Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$6.04M, down 139.7% year over year. For fiscal 2025 it was -$4.69M, down 118.5% from the year before. The highest annual figure on record is $25.38M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.69M | -118.5% |
| FY2024 | Dec 31, 2024 | $25.38M | +380.6% |
| FY2023 | Dec 31, 2023 | $5.28M | – |
| FY2022 | Dec 31, 2022 | -$12.23M | -364.2% |
| FY2021 | Dec 31, 2021 | $4.63M | -69.5% |
| FY2020 | Dec 31, 2020 | $15.16M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.37M | +1165.7% |
| Q1 FY2026 | Mar 31, 2026 | -$2.74M | – |
| Q4 FY2025 | Dec 31, 2025 | -$771.00K | -138.6% |
| Q3 FY2025 | Sep 30, 2025 | -$3.90M | -129.5% |
| Q2 FY2025 | Jun 30, 2025 | $108.00K | -98.3% |
| Q1 FY2025 | Mar 31, 2025 | -$125.00K | -103.2% |
| Q4 FY2024 | Dec 31, 2024 | $2.00M | -79.0% |
| Q3 FY2024 | Sep 30, 2024 | $13.22M | – |
| Q2 FY2024 | Jun 30, 2024 | $6.20M | – |
| Q1 FY2024 | Mar 31, 2024 | $3.96M | +38.5% |
| Q4 FY2023 | Dec 31, 2023 | $9.51M | +53.6% |
| Q3 FY2023 | Sep 30, 2023 | -$4.24M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.85M | – |
| Q1 FY2023 | Mar 31, 2023 | $2.86M | – |
| Q4 FY2022 | Dec 31, 2022 | $6.19M | +13.7% |
| Q3 FY2022 | Sep 30, 2022 | -$7.50M | -746.3% |
| Q2 FY2022 | Jun 30, 2022 | -$9.44M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.48M | -176.5% |
| Q4 FY2021 | Dec 31, 2021 | $5.45M | -53.2% |
| Q3 FY2021 | Sep 30, 2021 | $1.16M | -47.0% |
| Q2 FY2021 | Jun 30, 2021 | -$3.91M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.94M | – |
| Q4 FY2020 | Dec 31, 2020 | $11.64M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.19M | – |
See a number that looks wrong?